Finance. EHealth and Pharmaceuticals Directorate

Pharmacy and Medicines Division

T: 0131-244 2528

E: irene.fazakerley@scotland.gsi.gov.uk

The Scottish Government Riaghaltas na h-Alba

IMMEDIATE MESSAGE TO:

- 2. Chief Pharmacists NHS Boards
- 3. Hospital Pharmacy Managers
- 4. Medical Directors NHS Boards
- Chief Executives NHS Boards

12 June 2013

DRUG ALERT CLASS 2 no.16 2013 - action within 48 hours

Please see the attached drug alert for onward transmission as below. Could all Directors of Pharmacy please forward this alert to:-

- Community Pharmacists
- **Hospital Pharmacists**
- Chief Pharmacists to forward on to Medicines Information Pharmacists
- 1. Please could Medical Directors forward this alert to:-
 - **General Practitioners**
 - Accident & Emergency Departments
 - Directors of Public Health
 - Relevant Clinics
 - Chief Executives of NHS Board

Thank you for your co-operation.

Yours sincerely


IRENE FAZAKERLEY


Finance,e-Health and Pharmaceuticals Directorate













DRUG ALERT

CLASS 2 MEDICINES RECALL

Action Within 48 Hours Patient Level Recall

Date: 12 June 2013 EL (13)A/16 Our Ref: MDR 06-06/13

Dear Healthcare Professional,

Glaxo Wellcome UK Ltd trading as Allen & Hanburys

Ventolin Syrup sugar-free 2mg in 5ml (Salbutamol)

PL 10949/0088

Batch Number	Expiry Date	Pack Size	First Distributed					
M005	29 Feb 2016	150ml	26 Apr 2013					
M006	29 Feb 2016	150ml	26 Apr 2013					

Glaxo Wellcome UK Ltd is recalling the above batches because there is a potential risk of glass fragments in the bottles due to a defect which has been identified in a very small number of bottles. No complaints or adverse reactions relating to this issue have been received by the company to date.

Pharmacists and clinics are requested to contact patients to whom they have dispensed Ventolin Syrup sugar-free 2mg in 5ml since 26 April 2013 and ask them to return any remaining stock of these affected batches only. The company has informed us that alternative batches are available but due to this issue, the supply situation is currently fragile.

Please ensure that affected patients are not left without a supply. For stock information, please contact either AAH or Alliance Healthcare

NB only the above batches are affected by this issue. Please ensure that only stock from these batches is returned by patients as the supply situation is currently very fragile.

All unused stock of the listed batches should be quarantined and returned to the original supplier for credit. For returns and credit enquiries, please contact either AAH or Alliance Healthcare.

For medical information enquiries, please contact GlaxoSmithKline UK Medical Information Department on **0800 221441**, **option 2**

Cont/	 	 							

Medicines and Healthcare Products Regulatory Agency



Date: 12 June 2013 EL (13)A/16 MDR 06-06/13

Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. Local area teams are asked to forward this to relevant clinics, general practitioners and community pharmacists for information.

Yours faithfully

Alison Bunce
Pharmaceutical Assessor
Defective Medicines Report Centre
151 Buckingham Palace Road
London
SW1W 9SZ
Telephone +44 (0)20 3080 6574